I especially liked this bit:
Affimers are an antibody alternative, engineered to overcome the problems that have limited researchers. They are highly stable, biochemically inert offering rapid production of highly specific binding proteins in in vitro systems they are not limited by the immune repertoire. The development of Affimers finally opens up the required toolkit for proteomic researchers to target the proteome with a comprehensive set of affinity reagents that may enable scientists to elucidate protein function and identify key protein–protein interactions that are involved in disease states, thus providing critical links between our vast stores of genomic data and the urgent need for new therapeutics.
Which I translate into a very brief laymans type summary, to be something like:
"all the previous limitations on availability and lead times of antibodies are removed taking off the shackles borne by drug development companies since the beginning of time"
If these "Affirmers" do indeed do what they say on the tin, they open up a whole new era for all researchers and drug developers. Truly transformational.